Engage PharmaKonsult

Independent Perspective on Investment and Licensing Value

PharmaKonsult helps clinical-stage biotechnology companies test the assumptions behind a drug asset's investment value today and its licensing potential tomorrow—examining patient opportunity, differentiation, competition, and the development choices that could strengthen the investment case.

Why Joseph McCoy

With 36 years of biopharmaceutical commercial leadership across rare disease and specialty therapeutics, Joseph McCoy brings a perspective shaped by real-world commercialization experience. He helps leadership teams understand how evolving competition, treatment practices, physician behavior, and payer expectations may influence a therapy's future commercial potential — and how those insights can inform critical decisions before launch.

Experience that informs the analysis

  • 36 years of biopharmaceutical commercial leadership across rare disease and specialty therapeutics, including neuroscience, endocrinology, institutional healthcare, and complex treatment markets.
  • Built commercialization strategies for three emerging companies, addressing organizational design, launch planning, market development, patient and physician dynamics, and execution requirements.
  • Led successful product launches and growth initiatives, including products and regions that achieved #1 national performance.
  • Solved complex market-access and institutional barriers across commercial, federal, and specialty markets—experience that provides a practical view of what happens after a product leaves clinical development.
  • Built and led high-performance commercial organizations, with ten Pinnacle Club achievements and a sustained record of execution and growth.
  • Leadership experience across Pfizer, Lundbeck, SK Life Science, and Xeris, combining large-pharma operating discipline with the realities of emerging-company commercialization.
  • Former U.S. Navy Officer, bringing a decision-oriented approach grounded in accountability, preparation, and execution.
Joseph McCoy, PharmaKonsult

The value for emerging biotech

PharmaKonsult applies this downstream operating experience upstream—before major clinical-development and capital decisions become difficult or expensive to reverse.

The work complements the scientific, clinical, regulatory, and financial expertise already around a company by asking a different question:

Are the decisions being made today building toward a commercially viable product and an adequate return on the capital required to get there?

Where Biotechnology Leadership Engages PharmaKonsult

Practical perspective on decisions that affect whether clinical progress translates into investment value and future partnering attractiveness.

Commercial Decisions from Discovery through Phase 3

Bring commercial perspective into development decisions early—before clinical, market and investment assumptions become difficult to change.

Commercialize, Partner or License?

Evaluate the commercial opportunity, organizational requirements, investment and risk behind one of biotechnology’s most consequential strategic decisions.

Regulatory Pathway & Commercial Impact

Consider how regulatory strategy, indication sequencing, evidence requirements and potential labeling decisions may affect market opportunity and commercialization.

Is Your Culture Ready for What Comes Next?

Growth, clinical milestones and commercialization change organizations. Assess whether leadership, culture and ways of working are prepared for the company’s next stage.

Practice Areas

Supporting capabilities across development and value creation

Beyond the Investment & Asset Value Assessment, PharmaKonsult supports leadership across strategic development, specialty therapeutics, rare disease, and commercial leadership—capabilities that inform realistic investment and licensing assumptions.

Case Study

When Clinical Results Don't Drive Adoption

Pharmaceutical Commercialization · Market Analysis · HEOR

A new epilepsy therapy entered a crowded market with highly differentiated clinical results, including compelling seizure-freedom data. Yet adoption among some sophisticated epilepsy centers did not appear consistent with the strength of the clinical evidence. The important question wasn't whether the clinical data were strong—it was why strong clinical data weren't translating into expected market behavior.